{"id":"capecitabine-plus-temozolomide-vs-capecitabine","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Hand-foot syndrome"},{"rate":"20-30%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Capecitabine's mechanism of action is primarily through the inhibition of thymidylate synthase, which is necessary for DNA synthesis. This leads to the formation of DNA adducts, which prevent DNA replication and transcription. Temozolomide, on the other hand, is an alkylating agent that methylates DNA, leading to the formation of DNA adducts that trigger cell death in rapidly dividing cancer cells.","oneSentence":"Capecitabine is a prodrug that is converted into 5-fluorouracil, which interferes with DNA synthesis, thereby inhibiting cancer cell growth. Temozolomide works by methylating DNA, which triggers cell death in rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:49:01.404Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced breast cancer"},{"name":"Metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT03156036","phase":"PHASE2","title":"Preoperative CRT With Capecitabine ± Temozolomide in Patients With LARC","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2017-11-30","conditions":"Advanced Rectal Cancer","enrollment":64},{"nctId":"NCT02414009","phase":"PHASE2","title":"Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients","status":"COMPLETED","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2014-09","conditions":"Metastatic Colorectal Cancer","enrollment":82}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Temoram","Xeloda"],"phase":"phase_2","status":"active","brandName":"Capecitabine plus temozolomide VS Capecitabine","genericName":"Capecitabine plus temozolomide VS Capecitabine","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is a prodrug that is converted into 5-fluorouracil, which interferes with DNA synthesis, thereby inhibiting cancer cell growth. Temozolomide works by methylating DNA, which triggers cell death in rapidly dividing cancer cells. Used for Advanced breast cancer, Metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}